AdAlta

Updates

Home

Why Invest

Announcements

Lora

AdAlta’s “East to West” strategy has been validated and accelerated with additional term sheets

AdAlta’s “East to West” cellular immunotherapy strategy confirmed as key driver of future pipeline growth and value creation in strategic review and is core growth priority for the company

AdAlta will in-license highly differentiated cell therapies for solid cancers from Asian originators and build value by conducting first Phase I clinical trials.

This strategy provides a pathway for “Eastern” innovation to reach “Western” regulated markets and patients and aligns with a key driver of the global biopharma industry

Two new non-binding term sheets now signed following a disciplined asset selection process, bringing total products in advanced in-licensing discussions to three

Following a strategic review AdAlta’s first in class antifibrotic molecule, AD-214, will continue to be advanced only via third party transactions and the Company will cease internal discovery R&D activities to focus resources on the “East to West” growth strategy.